Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome

NCT07852234 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.

NCT NCT07852234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07852234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome
Lead sponsor
Beijing Tongren Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 25, 2026
Completion date
October 1, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary sjögren's syndrome (pss)